← Eichor
Study identifier: NCT07512284 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Mindfulness Engaged Neurostimulation for Depression (MEND II)

Condition: Depression · Treatment Resistant Depression · Major Depressive Disorder  ·  Sponsor: University of California, San Diego

PhasePhase 2
Planned participants120
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

This description comes directly from the study's public registry record.

Talk to the study team

Jyoti Mishra, PhD  ·  858-232-2855  ·  braine@ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UC San Diego Health PsychiatrySan Diego, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07512284